Furosemide as Supportive Therapy for COVID-19 Respiratory Failure
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study
the utility of nebulized furosemide for pulmonary inflammation in Intubated, mechanically
ventilated Patients with COVID-19.